| INTRODUCTION
Cancer incidence and mortality are expected to increase dramatically in Asia over the next 15 years, and patterns of diagnosis and treatment vary across this heterogenous and populous region. 1 Although recent years have seen a consistent emphasis on increasing cancer prevention screenings and effectively planning treatment programs, there is a need for effective new strategies to manage the rapidly growing disease burden of Asian patients with advanced cancers, especially esophageal and head and neck squamous cell cancer. 1, 2 Cyclin D-CDKs are enzyme complexes that serve as key regulators of cell cycle progression. 3 In cancers, the cyclin D-CDK4/6-INK4-Rb pathway is often altered, leading to dysregulated cell cycle progression. 3, 4 This dysregulation, which leads to increased cyclin D-CDK4/6 activity, may be the result of overexpression of cyclin D1, overexpression and mutation of CDK4, or loss of regulatory proteins such as p16. 3, 5 The expression of phosphorylated pRb, a canonical tumor suppressor, is maintained in the vast majority of cancers. 5, 6 Retinoblastoma-expressing tumor cells with dysregulation in the CDK4/6 pathway show particular sensitivity to CDK4/6 inhibition. 6 Ribociclib (LEE011) is an orally bioavailable, selective, small-molecule inhibitor of CDK4/6. 7 Preclinical studies of ribociclib reported cell cycle arrest and tumor growth inhibition in both in vivo and in vitro models in a variety of Rb+ solid tumor types. 8, 9 A phase I study of single-agent ribociclib in patients from the USA and Europe with Rb+ advanced solid tumors and lymphomas (NCT01237236)
confirmed ribociclib safety and tolerability at the RDE (600 mg/d, 3-weeks-on/1-week-off) and showed preliminary signs of clinical activity. 4 The objective of the present study (NCT01898845) was to determine the MTD and RDE of single-agent ribociclib in Japanese patients with Rb+ advanced solid tumors that have progressed on prior therapy. The safety, tolerability, PK, and preliminary antitumor activity for single-agent ribociclib were also assessed.
2 | ME TH ODS
| Study design and treatment
In this phase I, multicenter, single-arm, open-label study, Japanese patients with Rb+ advanced solid tumors were treated with singleagent ribociclib. Patients' Rb+ status was determined by testing of tumor samples by molecular screening at a sponsor-designated central laboratory. The primary objective of the study was to establish the MTD and/or the RDE for this patient cohort. Secondary objectives included the evaluation of safety and tolerability, antitumor efficacy, and PK properties for ribociclib.
In the dose-escalation portion of the study, groups of 3-6 patients received oral ribociclib on a 3-weeks-on/1-week-off schedule. The starting dose was based on MTD results (900 mg) from a phase I dose-escalation study in patients from the USA and Europe (NCT01237236). As this was the first clinical study of ribociclib in Asia, the starting dose was selected at 400 mg. After every evaluable patient in each group completed a minimum of one cycle of treatment or experienced a DLT, dose-escalation decisions were made by investigators and study personnel at dose-escalation meetings. In this study, a DLT was defined as a ≥grade 3 AE or abnormal laboratory value per the CTCAE version 4.03 10 that occurred during the DLT evaluation period and was determined by the investigator to be unrelated to disease, disease progression, or concomitant medication and to warrant classification as a DLT prior to the dose-escalation meeting. The recommended dose for the next group was guided by the adaptive BLRM with the EWOC principle. 11, 12 Dose escalation was planned to continue until identification of the MTD/ RDE, which was defined using the following criteria: when (i) at least 6 patients had been treated at this dose, and (ii.a) the dose had a more than 50% probability to have a true DLT rate between 16%
and 33% (targeted toxicity) and was the highest among potential doses, or (ii.b) a minimum of 12 patients had already received treatment on the study, and (iii) the dose was recommended for patients per the BLRM or review of all clinical data by investigators and sponsor.
In the dose-expansion portion of the study, a minimum of 12
Japanese patients with ESCC and at least one measureable lesion per RECIST version 1.1 were planned to be evaluated to determine the safety, preliminary antitumor activity, and PK profile for ribociclib. The sample size for the dose-expansion portion of the study was chosen to assess safety: at least 18 patients (comprising at least 6 patients from the dose-escalation portion and at least 12 patients from the dose-expansion portion) were required to be treated at the MTD/RDE for AEs occurring with a true incidence rate of ≥10% to have a probability of ≥85% for detection under the assumption that the true incidence rate was the same across the population enrolled.
| Patients
Adult Japanese patients with histologically confirmed advanced solid tumors that had progressed on conventional therapy, or for which no therapy was currently available, were eligible for the dose-escalation portion of the study. Tumors must have had centrally docu- 
| Study assessments
In the dose-escalation phase, the MTD/RDE for the 3-weeks-on/1-week-off dosing schedule was assessed by examination of the incidence and grade of DLTs during cycle 1. Efficacy was assessed by RECIST version 1.1 criteria using appropriate radiologic methods (computed tomography and MRI) or physical examination, depending on tumor type. All CRs and PRs had to be confirmed by a second assessment occurring at least 4 weeks after the initial antitumor response was observed. Incidence, duration, and severity of all AEs and their relationship to the study drug were assessed. Ribociclib plasma PK was assessed using sequential blood samples collected after study drug administration on cycle 1 day 1 and cycle 1 day 21 from all patients. Study data were analyzed when all patients in the dose-escalation portion had discontinued treatment.
3 | RESULTS
| Patient characteristics
From June 2013 to January 2015, a total of 17 patients were enrolled at 2 centers in Japan. The median patient age was 57.0 years, with 70.6% of patients <65 years old. Approximately half of the patients (52.9%) were women. The most common primary cancer was esophageal (n = 9, 52.9%), followed by breast (n = 4, 23.5%). All patients received prior antineoplastic therapy, with the majority (n = 12, 70.6%) having received 3 or more lines of prior antineoplastic medication and/or prior radiotherapy (n = 12, 70.6%) ( Table 1) .
| Dose escalation
Patients were enrolled in 2 dose levels, 400 mg ribociclib (n = 4) and 600 mg ribociclib (n = 13), both on 3-weeks-on/1-week-off dosing 
| Safety and tolerability
The median duration of exposure for all patients was 58.0 days. In the 400 mg dose group, the median duration of exposure was | 195 least one AE of ≥3 grade. The most frequent AEs were hematologic, followed by nausea and increased laboratory values. At the RDE, the most frequent treatment-related ≥3 grade AEs were leukopenia (85%), neutropenia (77%), lymphopenia (69%), thrombocytopenia (31%), and prolonged QT (15%) ( Table 2 ). The most frequent AEs of any grade were hematologic, a finding consistent with other studies of ribociclib. 4, 13 Hepatic AEs recorded during the study included increases in ALT, AST, and bilirubin. These AEs were generally mild, and none of them individually occurred in more than 2 patients. One patient experienced concurrent liver enzyme level elevations due to temporary blockage of bile flow from a metastatic retroperitoneal tumor, and as such did not meet the criteria for Hy's law. A total of 7 patients (1 patient in the 400 mg dose group and 6 patients at the RDE) experienced an electrocardiogram QT prolongation event, all of which were considered to be study drug-related ( Table 2 ). All events resolved without action, with the exception of a grade 3 QT prolongation event that resolved with dose interruption followed by restarting ribociclib at a lower dose.
No patient discontinued treatment due to an AE. A total of 3 patients in the study, all at the RDE, experienced a single serious AE (one each of grade 3 upper abdominal pain, grade 3 small intestinal obstruction, and grade 2 vomiting). Only a single serious AE (grade 2 vomiting) was suspected to be study drug-related.
There were no patient deaths during the treatment or safety follow-up period. Table 3 ). Elimination of ribociclib is dominated by oxidative metabolism, mainly through CYP3A4.
| Pharmacokinetic analysis
For the oxidative metabolite LEQ803, time to maximal concentration was similar to that of ribociclib, where the metabolite-to-parent ratio AUC 0-24 h was 0.15 at the 400 mg dose and was a smaller ratio (0.08) at the higher 600 mg dose (the RDE).
| Efficacy
All patients in the study were heavily pretreated (Table 1 
ECG, electrocardiogram; PPE, palmar-plantar erythrodysesthesia.
(12%) discontinued treatment per physician decision. As no signs of clinical activity were observed for the 9 ESCC patients treated in the dose-escalation portion of the study, the planned dose expansion did not proceed.
| DISCUSSION
In this phase I study in adult Japanese patients with Rb+ advanced solid tumors whose disease had progressed on prior therapy, the RDE of single-agent ribociclib was determined to be 600 mg on a 3-weeks-on/1-week-off schedule. At the doses investigated in this study, single-agent ribociclib showed an acceptable safety and tolerability profile, with limited preliminary clinical activity. The results of the study were consistent with a phase I study of adult patients with solid tumors carried out in the USA and Europe. 4 A total of 17 patients were enrolled (4 patients in the 400 mg dose group and 13 patients in the 600 mg dose group). A total of 4 patients in the study experienced DLTs (1 patient in the 400 mg dose group and 3 patients in the 600 mg dose group). All toxicities were well managed by dose adjustment or interruption. The 2 DLTs of grade 3 QT prolongation at the RDE were resolved (one without action and one with dose interruption followed by dose reduction).
The most frequently reported AEs were hematologic (leukopenia, neutropenia, lymphopenia, thrombocytopenia, and anemia). Hepatic
AEs were generally grade 1/2, and occurred at rates similar to those observed in a phase I clinical trial of single-agent ribociclib in patients from the USA and Europe. 5 Hematologic AEs were also the most frequent grade ≥3 AEs, and occurred more frequently than in previous studies in non-Japanese patients. Single-agent ribociclib at the RDE showed acceptable tolerability for Japanese patients with advanced solid tumors, with no major differences in the safety profile observed from previous studies in other patient populations. 13 Ribociclib exposure increased with increasing dose, and exposure accumulation occurred after repeat dosing. The clearance of parent drug and the metabolite-to-parent AUC ratio were reduced for the 600 mg dose vs the 400 mg dose, suggesting a change in metabolism with increasing doses, which could be due to saturation in metabolism and/or auto-inhibition of CYP3A4, as reversible and timedependent inhibition of CYP3A4/5 has been observed in vitro.
14 Although the exposures at both dose levels (400 and 600 mg) were higher on average than those observed in a phase I clinical trial of single-agent ribociclib in patients from the USA and Europe, 4 interindividual variability also was observed (Table 3) , and the range of individual values overlapped between studies. Therefore, no conclusions could be made for PK ethnic sensitivity in this study. 
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